University of Kentucky Research Foundation has sold Coldstream Laboratories to Piramal Enterprises Limited
Lincoln International (“Lincoln”), a leading global mid-market investment bank, is pleased to announce that Coldstream Laboratories, Inc. (“Coldstream” or the “Company”) has been sold by University of Kentucky Research Foundation to Piramal Enterprises Limited.
Headquartered in Lexington, Kentucky, Coldstream is a specialty pharmaceutical contract manufacturer with an emphasis on clinical trial to commercial-scale sterile manufacturing of liquid and lyophilized parenterals and injectables. The Company leverages its differentiated expertise and state-of-the-art facility to serve a diverse customer base of branded and generic pharmaceutical and biotech companies. Coldstream’s complex product capabilities include parenteral manufacturing for liquid and lyophilized products, ISO class 5 processing and high containment for sterile fill/finish of potent and cytotoxic products and analytical and formulation development support services.
Lincoln acted as the exclusive financial advisor to Coldstream and its majority shareholder, the University of Kentucky Research Foundation, working closely with the Company’s board of directors and management team throughout the sale process. This included providing advisory expertise and managing the preparatory marketing, negotiation and due diligence phases of the transaction.
Meet Our Professionals
View More Transactions
Lincoln International Advises Livermore Software Technology Corporation on their announced sale to ANSYS, Inc.
Lincoln International advises Memira, a portfolio company of Patricia Industries, in its sale to Bergman Clinics
Lincoln International is pleased to announce the sale of Nedap France to B & Capital and its management team
Lincoln International is pleased to announce the sale of Pacific Design Technologies to AMETEK